Guest Column: What Federal Cannabis Rescheduling Means and Why South Dakota’s Medical Cannabis Law Remains Essential for Patients and Public Safety By Emmett Reistroffer
What Federal Cannabis Rescheduling Means and Why South Dakota’s Medical Cannabis Law Remains Essential for Patients and Public Safety
By Emmett Reistroffer

President Trump’s recent executive order directing the rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act is a significant and historic step toward potential federal reform. But it is only that—a first step. Any actual change will unfold through a lengthy, uncertain process that could take years before it produces meaningful, on-the-ground effects.
Still, the announcement has understandably sparked (pun intended) widespread interest and confusion, particularly among the more than 18,000 South Dakotans who currently rely on our state’s voter-approved medical cannabis program for safe and lawful access. Questions are fair. Misinformation is not.
As someone who has spent years advocating for safe medical cannabis access—and who now works daily with patients, caregivers, regulators, local governments, and licensed operators across South Dakota—I believe it is important to set the record straight. Patients, providers, and community leaders deserve clarity. Unfortunately, some politicians appear eager to exploit uncertainty as an opportunity to undo progress backed by an overwhelming majority of voters.
South Dakota’s medical cannabis law — now SDCL 34-20G — was built deliberately, carefully, and democratically. It provides patient protections, oversight by physicians and other medical providers, controlled licensing, product testing, and strict regulatory enforcement. It is not a loophole, a commercialization scheme, the wild west, or a policy accident. It is a medical framework supported by veterans, chronic-pain patients, cancer survivors, families, and healthcare professionals who support a safer alternative to opioids and criminalization.
The claim that federal rescheduling somehow makes South Dakota’s voter-approved medical cannabis program unnecessary misunderstands both what rescheduling is and what it actually changes in practice.
First – Why Did President Trump Take Action?
The opening section of President Trump’s executive order clearly states the policy rationale behind directing federal agencies to reconsider marijuana’s classification.
“Chronic pain affects nearly 1 in 4 United States adults and more than 1 in 3 United States seniors, and 6 in 10 people who use medical marijuana report doing so to manage pain. Forty States plus the District of Columbia have State- or locally-sanctioned, regulated medical marijuana programs. Yet decades of Federal drug control policy have neglected marijuana’s medical uses. That oversight has limited the ability of scientists and manufacturers to complete the necessary research on safety and efficacy to inform doctors and patients.”
In short, the executive order recognizes a reality that patients, physicians, and states have already confronted: federal policy has failed to keep pace with medical evidence and real-human experience.
This action reflects Donald Trump’s populist governing approach—addressing issues directly, grounding policy in observable facts, and prioritizing the lived experiences of Americans over outdated assumptions. It does not legalize marijuana, nor does it dismantle state authority. Instead, it acknowledges medical use, encourages research, and begins correcting a long-standing federal and state conflict.
That context matters—because the executive order was not issued to replace state medical cannabis programs like South Dakota’s, but to begin aligning federal policy with what the American people want and what most U.S. states have worked on for decades.
What Federal Rescheduling Really Means — and What It Doesn’t
The shift toward moving marijuana from Schedule I to Schedule III is meaningful — but it is not federal legalization, and it is not a replacement for state medical cannabis programs. It’s also not a guarantee that anything will change – it simply allows a pathway to change.
Rescheduling happens through formal DEA rulemaking process that includes scientific review, public comment, and final rule publication. The process is further affected by other agency involvement and input and even Congressional action. This will take, at least, several months — but more likely, years — and potentially longer if litigation occurs. Until rescheduling is final, cannabis remains Schedule I under federal law.
Even if rescheduling is finalized, marijuana will still be a controlled substance under the Controlled Substances Act. It will not become broadly available as a federally prescribed medication unless and until there is full FDA approval to be dispensed in pharmacies.
Physicians in South Dakota issue medical certifications, not federal prescriptions — and rescheduling does not convert our program into a federal prescription system.
In practical terms, rescheduling does three important things:
- It formally acknowledges legitimate medical use
- It reduces research barriers to legitimate scientific research
- It allows relief from the punitive IRS 280E tax restriction on state-licensed medical cannabis businesses
Those are positive steps — and a long list of various organizations and the vast majority of Americans, including Veterans, patients, medical providers and researchers support rescheduling because it strengthens and stabilizes state medical cannabis programs — not because it replaces them.
What Rescheduling Does Not Fix
Rescheduling alone does not resolve the core conflicts between federal and state law.
Congress would still need to act to:
- harmonize federal criminal statutes with state-regulated systems
- address interstate transport and commerce rules
- modernize banking and financial protections
- establish an appropriate federal framework for medical cannabis access
- preserve state regulatory authority
South Dakota’s medical cannabis program remains essential until these issues are addressed and safe access for patients is guaranteed.
If South Dakota repealed SDCL 34-20G today, there would be:
- no federal replacement structure ready
- no federal prescription access available
- no legal framework protecting patients
- no oversight system for quality, safety, or testing
Repeal would not “defer to federal law.”
Ultimately, repeal would simply remove patient protections and re-criminalize sick and dying South Dakotans – whom 70% of voters decided deserve compassion, dignity, safe access and legal protection.
A small group of newly elected lawmakers, led by a vocal anti-marijuana activist, are calling to return South Dakota back to a time when sick and dying patients had to get cannabis from street dealers and risk jail or prison time, just to find relief and manage paint – folks with chronic pain, seizures, or PTSD among many others.
I believe a more reasonable, conservative and compassionate approach is to respect the will of the voters and focus on program improvements instead – working together to ensure safe access to medical cannabis with proper oversight.
South Dakota’s Program Reflects This Approach.
Maintaining the voter-approved medical cannabis program means:
- regulated rather than chaotic
- physician-guided rather than street-driven
- tested and tracked rather than unmonitored
- accountable to state agencies rather than cartels or illicit suppliers
Our Department of Health, local governments, and licensed operators have invested years and millions of dollars into building a secure, compliant system — one that prioritizes safety, product integrity, and an overall responsible approach to handling medical cannabis.
Repealing the voter-approved law and current program would:
- destabilize communities
- endanger patients and create unnecessary risks for them and their families
- embolden street dealers and make the black market more lucrative
- and undo the will of South Dakota voters
Federal reform should support and complement South Dakota’s voter-approved and state-regulated medical cannabis program — not erase it.
The Responsible Path Forward
Rescheduling is progress — but it is not a finish line.
The responsible and principled approach is to:
- maintain the voter-approved medical cannabis law (SDCL 34-20G
- continue improving the program to ensure every patient who qualifies has the option for safe access to medical cannabis
- work with regulators and stakeholders to ensure regulations are reasonable and fair
- align where appropriate with evolving federal policy
- advocate for Congressional action that respects state sovereignty
South Dakotans support a program rooted in compassion and common-sense oversight. We should not abandon that work — but steward it wisely as federal policy finally begins to catch up. While President Trump’s executive order is a positive step in the right direction, South Dakota is ultimately better positioned to deliver on the needs and desires of our own people and should remain in control of our own medical cannabis policy — rather than rely and wait on Washington bureaucracy.
—
Emmett Reistroffer is the Director of Government Relations for Genesis Farms, based in Box Elder, SD and is a Republican candidate for the South Dakota House of Representatives, District 35


Sioux Falls, S.D. – Today, Representative Amber Arlint announced that she is running for re-election to the South Dakota House of Representatives in District 12, reaffirming her commitment to serving her constituents by improving education, keeping neighborhoods safe, and supporting an economy that rewards hard work and creates opportunity here at home.







